Vikas Dandekar is the Chief Editor for News at The Economic Times, with a focus on local news in Mumbai, India. He covers a wide range of topics, including business, economics, healthcare, and technology. Vikas is known for his insightful articles that provide valuable insights into the Indian market and its impact on various industries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Vikas Dandekar's coverage is heavily focused on healthcare, pharmaceuticals, and health-related topics in India with a specific emphasis on Mumbai. It seems he would be most interested in expert commentary from professionals within the healthcare and pharmaceutical industries regarding prevailing issues such as diabetes management, heart ailments, medical research breakthroughs, and regulatory changes.
If you have expertise or insights related to these areas or can provide analysis of government announcements impacting the healthcare sector in India (especially Mumbai), your pitch may resonate well with Vikas. Additionally, if you represent an organization making significant contributions to this industry locally or nationally, it could also capture his interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Reghu Balakrishnan, Arijit Barman, Vikas Dandekar
Torrent Pharma and Zydus Lifesciences are vying to acquire JB Chemicals and Pharmaceuticals, with both firms shortlisted by KKR, the current owner. Torrent has started discussions with banks for financing, while private equity firm EQT is also expected to participate. Dr. Reddys Laboratories has shown interest but has yet to submit an offer.
By: Vikas Dandekar
Priya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor followed global guidelines, while the second used Indian ones, stabilizing her condition. The case underscores different diabetic treatment protocols and the importance of tailored patient care in India.
By: Vikas Dandekar
Priya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor followed global guidelines, while the second used Indian ones, stabilizing her condition. The case underscores different diabetic treatment protocols and the importance of tailored patient care in India.
By: Vikas Dandekar
Mpox is the latest scare word ripping through the world. The pressing questions are: Is a deadly pandemic like Covid-19 already here?
By: Vikas Dandekar
The mpox virus that started from Central Africa has now reached Europe and closer to home, Pakistan. While its too early to gauge the threat of a potential pandemic, India must prioritise countermeasures and prepare for possible outbreaks.
By: Vikas Dandekar
Experts believe with a few exceptions, much of the combination drugs launched in India may have less to do with convincing therapeutic rationale or
It may sound astonishing, but Covid-19 still kills 1700 each week. No forecasts of “flattening the curve” have gone right.
Exactly a month ago, a doctor was brutally raped and murdered inside a large hospital in Kolkata. As a young chest physician in training, she won the hearts of patients.
By: Vikas Dandekar
GE HealthCare is riding high on the India opportunity. Speaking exclusively to ET Prime, Chaitanya Sarawate, president and CEO of GE HealthCare South Asia and managing director of Wipro GE Healthcare, discusses why the magic is in building localised products.
By: Vikas Dandekar
GE HealthCare is riding high on the India opportunity. Speaking exclusively to ET Prime, Chaitanya Sarawate, president and CEO of GE HealthCare South Asia and managing director of Wipro GE Healthcare, discusses why the magic is in building localised products.
(833) 317-6278 
